TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Active Biotech AB ( (SE:ACTI) ) is now available.
Active Biotech AB has announced a fully secured rights issue to raise approximately SEK 70 million, aimed at funding ongoing studies of tasquinimod in myelofibrosis and the development of laquinimod for inflammatory eye diseases. This financial move is expected to support the company’s strategic focus on advancing its clinical trials and business development activities, potentially enhancing its position in the biotech industry by addressing diseases with high unmet medical needs.
More about Active Biotech AB
Active Biotech is a Swedish biotech company focused on developing innovative immunomodulatory therapies for diseases with high unmet medical need, particularly in hematological malignancies and inflammatory eye diseases. The company is advancing two key compounds, tasquinimod and laquinimod, which have shown promise in previous studies and are supported by extensive data and global patents.
YTD Price Performance: 44.44%
Average Trading Volume: 4,892,505
Technical Sentiment Signal: Sell
Current Market Cap: SEK192.6M
For an in-depth examination of ACTI stock, go to TipRanks’ Overview page.